Activin and Inhibin

I-138 is an orally active compound structurally related to ML323 ( HY-17543 ). I-138 and ML-323 are potent reversible inhibitors of USP1-UAF1. I-138 displays synergistic binding with ubiquitin and mutual exclusive binding with ML323. I-138 induces

I-138 is an orally active compound structurally related to ML323 ( HY-17543 ). I-138 and ML-323 are potent reversible inhibitors of USP1-UAF1. I-138 displays synergistic binding with ubiquitin and mutual exclusive binding with ML323. I-138 induces

I-191 is a potent, selective protease-activated receptor 2 (PAR2) antagonistIn VitroI-191 inhibits cytokine production as well as cytokine-related caspase cleavages via ERK1/2 signaling in HT29 colon cancer cells. MCE has not independently confirmed

I-191 is a potent, selective protease-activated receptor 2 (PAR2) antagonistIn VitroI-191 inhibits cytokine production as well as cytokine-related caspase cleavages via ERK1/2 signaling in HT29 colon cancer cells. MCE has not independently confirmed

I-191 is a potent, selective protease-activated receptor 2 (PAR2) antagonistIn VitroI-191 inhibits cytokine production as well as cytokine-related caspase cleavages via ERK1/2 signaling in HT29 colon cancer cells. MCE has not independently confirmed

I-191 is a potent, selective protease-activated receptor 2 (PAR2) antagonistIn VitroI-191 inhibits cytokine production as well as cytokine-related caspase cleavages via ERK1/2 signaling in HT29 colon cancer cells. MCE has not independently confirmed

I-191 is a potent, selective protease-activated receptor 2 (PAR2) antagonistIn VitroI-191 inhibits cytokine production as well as cytokine-related caspase cleavages via ERK1/2 signaling in HT29 colon cancer cells. MCE has not independently confirmed

I-191 is a potent, selective protease-activated receptor 2 (PAR2) antagonistIn VitroI-191 inhibits cytokine production as well as cytokine-related caspase cleavages via ERK1/2 signaling in HT29 colon cancer cells. MCE has not independently confirmed

I-BET282 is a pan-inhibitor of all eight BET bromodomains , and selectivity over other representative bromodomain-containing proteins. I-BET282 shows pIC 50 s ranging 6.4-7.7 for BRD2 (BD1/BD2), BRD2 (BD1/BD), BRD3 (BD1/BD), and BRD4 (BD1/BD).In

I-BET282 is a pan-inhibitor of all eight BET bromodomains , and selectivity over other representative bromodomain-containing proteins. I-BET282 shows pIC 50 s ranging 6.4-7.7 for BRD2 (BD1/BD2), BRD2 (BD1/BD), BRD3 (BD1/BD), and BRD4 (BD1/BD).In

I-BET282 is a pan-inhibitor of all eight BET bromodomains , and selectivity over other representative bromodomain-containing proteins. I-BET282 shows pIC 50 s ranging 6.4-7.7 for BRD2 (BD1/BD2), BRD2 (BD1/BD), BRD3 (BD1/BD), and BRD4 (BD1/BD).In

I-BET282 is a pan-inhibitor of all eight BET bromodomains , and selectivity over other representative bromodomain-containing proteins. I-BET282 shows pIC 50 s ranging 6.4-7.7 for BRD2 (BD1/BD2), BRD2 (BD1/BD), BRD3 (BD1/BD), and BRD4 (BD1/BD).In